Dr. Daniel K. Storey, M.D.
Family Medicine (Family Medicine Physician)
Who else practices at this address →
Northeastern Connecticut Planning Region is a federal primary care shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 165
Licensed in Connecticut since 2025, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Chicago, Pritzker School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
CT license 83014 (first issued 2025; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hendricks Regional Health Danville, IN
- Iu Health West Hospital Avon, IN
- Day Kimball Hospital Putnam, CT
Medical groups
- Day Kimball Medical Group Inc (89 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 165
- Services billed
- 1,024
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 245 | 150 |
| Insertion of needle into vein for collection of blood sample | 238 | 142 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 91 | 91 |
| Established patient office or other outpatient visit, 20-29 minutes | 88 | 84 |
| Administration of influenza virus vaccine | 41 | 41 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 36 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Putnam, CT | 498 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Putnam, CT | 361 |
| Lisinopril Other prescribers in Putnam, CT | 315 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Putnam, CT | 268 |
| Levothyroxine Sodium Other prescribers in Putnam, CT | 243 |
| Gabapentin Other prescribers in Putnam, CT | 230 |
| Amlodipine Besylate Other prescribers in Putnam, CT | 216 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Putnam, CT | 207 |
| Omeprazole Other prescribers in Putnam, CT | 187 |
| Pantoprazole Sodium Other prescribers in Putnam, CT | 177 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $31.74 in total to this clinician.
| Exact Sciences Corporation | $31.74 |
|---|
| Food and Beverage | $31.74 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $258,588 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
AbbVie Inc. · Active, not recruiting · NCT04333576 - M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Sev…
AbbVie Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.